Finland· FI-REL-REL11093

Purevax Felv

A elävät virusrokotteet product containing canarypoxvirus (vcp97), felv recombinant, live, registered in Finland by Merial S.A.S.

ATC QI06AD

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedPurevax FelvATCQI06ADREGISTER NO.FI-REL-REL11093PACKS LISTED0CHECKEDSeptember 27, 2026

The record

At a glance

Fimea (Finland)
Active substance
Canarypoxvirus (vCP97), FeLV recombinant, live
Manufacturer
Merial S.A.S
Country
Finland (FI)
ATC code
QI06AD
ATC class
Elävät virusrokotteet
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b68523d1-13ee-491a-a277-5625d1380938
GET /v1/drugs/b68523d1-13ee-491a-a277-5625d1380938?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektiokuiva-aine, kylmäkuivattu ja liuotin, suspensiota varten",
  "route": "Ihon alle",
  "ddd_unit": null,
  "strength": null,
  "atc_label": "Elävät virusrokotteet",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/2/00/19/01-03",
  "fimea_rel_id": "REL11093",
  "authorised_at": "2000-04-13"
}

See everything about canarypoxvirus (vcp97), felv recombinant, live.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.